My HPRA: Register

The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Seretide 125 Evohaler 25 microgram/125 microgram/dose pressurised inhalation, suspension



GlaxoSmithKline (Ireland) LimitedPA1077/046/005

Main Information

Trade NameSeretide 125 Evohaler 25 microgram/125 microgram/dose pressurised inhalation, suspension
Active SubstancesSALMETEROL XINAFOATE
Fluticasone propionate
Dosage FormPressurised inhalation, suspension
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberPA1077/046/005

Group Information

ATC CodeR03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
R03AK06 salmeterol and fluticasone

Status

License statusAuthorised
Licence Issued23/02/2001
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable ListSalmeterol/Fluticasone 25mcg/125mcg Pressurised Inhalation Suspension
Interchangeable List CodeIC0128-176-053
Interchangeable List DocumentPDF of Interchangeable List
« Back
Follow medicine

Print